Curriculum Vitae

Mark Melden, DO
Subinvestigator

Signature: _____ Date: 5/12/14

Licensure and Specialty

Licensure: Doctor of Osteopathy (DO), License #20A 7900, California
Specialty: Psychiatry, Board Certified

Site Affiliation

North County Clinical Research
3230 Waring Court, Suite P
Oceanside, California 92056
Phone: 760-639-4378
Fax: 760-639-4379

Current Hospital Affiliations

Bayview Hospital and Mental Health
330 Moss St
Chula Vista, CA 91911

Paradise Valley Hospital
2400 East 4th Street
National City, California 91950

Sharp Coronado Hospital
250 Prospect Place
Coronado, CA 92118

Sharp Mesa Vista Hospital
7850 Vista Hill Avenue
San Diego, CA 92123

TriCity Medical Center
4002 Vista Way
Oceanside, California 92056

Professional Affiliation/Education

2002 to 2005	Residency, Psychiatry University of California at Irvine Irvine, California
2000 to 2002	Residency, Family Practice/Medicine University of Southern California – Presbyterian Intercommunity Hospital Los Angeles/Whittier, California
1999	Doctorate of Osteopathic Medicine Philadelphia College of Osteopathic Medicine Philadelphia, Pennsylvania
1995	Bachelor of Science - Major: Biochemistry, Minor: Psychology and Film University of California, San Diego La Jolla, California

Professional Experience

May 2011 to Present	Subinvestigator North County Clinical Research, Oceanside, California

2010 to Present	Medical Executive Committee Paradise Valley Hospital, National City, California
2010 to Present	Medical Director Tri-City Medical Center, Oceanside, California
2010 to Present	Adjunct Clinical Instructor Lake Erie College of Osteopathic Medicine, Erie, Pennsylvania
2009 to Present	Medical Director Tele-Care CORE Program, Los Angeles, California
2009 to 2010	Medical Director Fountain Valley Regional Sleep Center, Fountain Valley, California
2007 to Present	Medical Director/Chairman Sharp Coronado Behavioral Health Outpatient Unit, Coronado, California
2005 to Present	Medical Director Hanbeleceya Therapeutic Community System, La Mesa, California
2005 to Present	Medical Director/Owner/CEO Crownview Medical Group, Inc., Coronado, California
2002 to 2005	Locum Tenens, Psychiatry California Department of Corrections, Geriatric Psychiatry, Nursing Home, Long-Term Psychiatric Facilities
2000 to 2002	Locum Tenens: Family Medicine Urgent Care, Family Practice, Community Clinics, General Practices, Industrial, and Occupational Medicine

Other Professional Experience

June 1996 to September 1996
Research and Development Associate Scientist
Raiziss Fellowship Recipient University of Pennsylvania, Philadelphia, Pennsylvania
Synthesized a-helices to answer the scientific debate about whether proteins begin to fold before or after their secondary structures. Publication is pending on this research.

November 1994 to June 1995
Research and Development Associate Scientist
DuPont Merck Pharmaceutical Co., Wilmington, Delaware
Utilized combinatorial chemistry and structure-based ligand design to develop a novel class of compounds that inhibit collagenase implicated in both cancer metastasis and arthritis.

November 1994 to February 1995
Mental Health Counselor
Transitional Residency Independent Service, Inc., Berlin, New Jersey
Conducted group and individual counseling sessions for mentally ill patients to assist them in the transition to outpatient living.

Publications

Journal of American Chemical Society, Vol. 118, No. 42, (10337) 1996
Complimentary of Combinatorial Chemistry and Structure-Based Ligand Design:
Application to the Discovery of Novel Inhibitors of Matrix Metalloproteinases.

Ann Pharmacother. 2004 May; 38(5):899-900. Epud 2004 Mar 23
Urinary retention following repeated high-dose quetiapine.

Research Assistantships

NATIONAL INSTITUTES OF HEALTH, Summer 1998 Preceptor: Dr. Monica Skarulis
Worked at the Endocinology/Metabolism branch of the NH involved with a variety of protocols using experimental medications and surgeries for different endocrine diseases

UCSD MEDICAL CENTER, Spring 1992 to Fall 1992 Supervisor: Dr. W. Perry
Learned to administer and evaluate Rorschach blots given to patients who suffer from schizophrenia

Training and Certifications

2010 to Present National Institutes of Health (NIH) Training and Certification

Honors and Awards

1995 Graduated Cum Laude, University of California, San Diego, California
1995 Dean's Award for Academic Excellence for four semesters, University of California, San Diego, California

North County Clinical Research

Clinical Research Trials

Mark Melden, DO

Year Started	Phase	Indication	Protocol Title
2014	Phase 3	Major Depressive Disorder	A phase 3 efficacy and safety study of XXXX for the adjunctive treatment of major depressive disorder
2014	Phase 3	Neuropathic Pain	A randomized double-blind placebo controlled parallel group study of the efficacy and safety of XXXX (BID) in subjects with post-traumatic peripheral neuropathic pain
2013	Phase 2	Cocaine Dependency	A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once-weekly intra-muscular injections of XXXX (150 mg/week or 300 mg/week) as treatment for facilitation of abstinence in cocaine-dependent subjects
2013	Phase 2	Schizophrenia	A phase 2, randomized, multicenter, safety, tolerability, and dose-ranging study of XXXX, a component of XXXX, in adults with schizophrenia treated with XXXX
2013	Phase 3	Major Depressive Disorder	A phase 3, long-term, open-label study of safety and tolerability of XXXX as adjunctive therapy in major depressive disorder
2013	Phase 3	Opioid Dependence	A randomized, blinded, active-controlled non-inferiority study of the efficacy and safety of XXXX for the induction of treatment of opioid dependence
2013	Phase 3	Opioid Dependence	Phase III - A multi-center, open-label, 24-week, follow-up study to assess safety, efficacy and treatment adherence for maintenance treatment of opioid dependence with XXXX
2013	Phase 3	Schizophrenia	A phase 3, multicenter, extension of Study XXXX to assess the long-term safety and durability of effect of XXXX in subjects with stable schizophrenia
2013	Phase 3b	Schizophrenia	An exploratory, multicenter, open-label, monotherapy, flexible-dose XXXX (XXXX) trial in adults with early episode schizophrenia
2013	Phase 4	Adolescent Smoking Cessation	A twelve week, randomized, double blind, placebo controlled, parallel group, dose ranging study with follow up evaluating the safety and efficacy of XXXX for smoking cessation in healthy adolescent smokers
2012	Phase 2	Bipolar I Disorder	A prospective, randomized, double-blind, placebo-controlled, phase 2 safety and efficacy study of oral XXXX as an adjunctive maintenance treatment in patients with bipolar I disorder

2012	Phase 3	Bipolar 1 Disorder with Depression	A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of once a day, XXXX (XXXX) tablet for sublingual administration (XXXX Tablet) 0.1 mg and 0.4 mg as an adjunctive therapy in the treatment of acute depressive episodes associated with bipolar 1 disorder in adult subjects
2012	Phase 3	Bipolar 1 Disorder with Depression	A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of once a day, XXXX 0.1 and 0.4 mg as an adjunctive therapy to treatment-as-usual in the maintenance treatment of bipolar 1 disorder in adult subjects
2012	Phase 3	Bipolar I Disorder	A 52-week, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of XXXX (XXXX) as maintenance treatment in patients with bipolar I disorder
2012	Phase 3	Bipolar I Disorder	A 52-week, multicenter, open-label study to evaluate the effectiveness of an intramuscular depot formulation of XXXX (XXXX) as maintenance treatment in patients with bipolar I disorder
2012	Phase 3	Major Depressive Disorder	A phase 3, double-blind, placebo-controlled study of XXXX as adjunctive therapy in major depressive disorder
2012	Phase 3	Major Depressive Disorder	Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible dose titration, efficacy and safety study of XXXX in combination with an antidepressant in the treatment of adults with major depressive disorder with inadequate response to prospective treatment with an antidepressant
2012	Phase 3	Major Depressive Disorder	A phase 3, open-label, multicenter, 12-month extension safety and tolerability study of XXXX in combination with an antidepressant in the treatment of adults with major depressive disorder with residual symptoms or inadequate response following treatment with an antidepressant
2012	Phase 3	Schizophrenia	A phase 3, multicenter, extension of study XXXX to assess the long-term safety and durability of effect of XXXX in subjects with stable schizophrenia
2012	Phase 3	Schizophrenia	A phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of XXXX in subjects with acute exacerbation of schizophrenia
2012	Phase 3	Schizophrenia	A randomized, double-blind, placebo-controlled, parallel, 12-week, phase 3 study of 2 doses of an XXXX XXXX XXXX XXXX XXXX (XXXX) or placebo as an adjunctive pro-cognitive treatment in schizophrenia subjects on chronic stable atypical antipsychotic therapy
2012	Phase 3	Schizophrenia	A multicenter 40-week extension study to evaluate the safety and clinical effects of prolonged exposure to 1 and 2 mg doses of XXXX, an XXXX XXXX XXXX XXXX XXXX, as an adjunctive pro-cognitive treatment in subjects with schizophrenia on chronic stable atypical antipsychotic therapy

2012	Phase 3	Schizophrenia	A randomized, multicenter, double-blind, non-inferiority study of XXXX XXXX 3 month and 1 month formulations for the treatment of subjects with schizophrenia
2012	Phase 3	Schizophrenia	A 12-week, phase 3, multicenter, randomized, double blind, placebo-controlled trial of XXXX intramuscular depot (XXXX) in the acute treatment of adults with schizophrenia
2012	Phase 3	Schizophrenia	A 26-week, multicenter, open-label, extension study of XXXX intramuscular depot (XXXX) in patients with schizophrenia
2012	Phase 4	Smoking Cessation Cardiac Assessments	A phase 4, non-treatment follow-up for cardiac assessments following use of smoking cessation treatments in subjects with and without a history of psychiatric disorders
2011	Phase 2	Major Depressive Disorder	A randomized, double-blind, placebo-controlled, parallel group, phase 2 study of XXXX in subjects with major depressive disorder
2011	Phase 2	Schizophrenia	Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of XXXX in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo-controlled treatment period
2011	Phase 2	Schizophrenia	A phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of XXXX in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period
2011	Phase 3	Major Depression Associated with Bipolar I Disorder	A double-blind, placebo-controlled, parallel-group, fixed-dosage study to evaluate the efficacy and safety of XXXX Treatment (150 and 200 mg/day) as adjunctive therapy in adults with major depression associated with bipolar I disorder
2011	Phase 3	Major Depression Associated with Bipolar I Disorder	A 6 month, open-label, flexible-dosage (150 to 200 mg/day) extension study of the safety and efficacy of XXXX treatment as adjunctive therapy in adults with major depression associated with bipolar I disorder
2011	Phase 3	Major Depressive Disorder	A phase 3, long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of XXXX (15 and 20 mg) in subjects with major depressive disorder
2011	Phase 3	Major Depressive Disorder	A phase 3, randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of XXXX in acute treatment of adults with major depressive disorder
2011	Phase 3b	Schizophrenia	A multicenter, open-label study to assess hospitalization rates in adult subjects with schizophrenia treated prospectively for 6 months with XXXX IM Depot compared with 6-month retrospective treatment with oral antipsychotics in a naturalistic community setting in the united states

2011	Phase 4	Schizophrenia	A 12-week, randomized, multi-center, open-label, XXXX, (12-24mg/day), flexible dose study assessing efficacy, safety and tolerability of two switch approaches in schizophrenia patients currently receiving XXXX, XXXX or XXXX
2011	Phase 4	Smoking Cessation	A phase 4, randomized , double-blind, active and placebo-controlled, multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks XXXX XXXX 1mg BID and XXXX XXXX 150mg BID for smoking cessation in subjects with and without a history of pschiatric disorders
2010	Phase 3	Major Depressive Disorder	A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase III, efficacy and safety study of 3 fixed dose groups of XXXX (XXXX) as an adjunct to an antidepressant in patients with major depressive disorder who exhibit an inadequate response to antidepressant therapy
2010	Phase 3	Opioid Addiction	A phase 3, six-month, open-label re-treatment study of XXXX in opioid addiction
2010	Phase 3	Opioid Dependence	A randomized, placebo and active-controlled, multi-center study of XXXX in patients with opioid dependence
2010	Phase 4	Schizophrenia	A fifteen-month, prospective, randomized, active-controlled, open-label, flexible dose study of XXXX XXXX compared with oral antipsychotic treatment in delaying time to treatment failure in adults with schizophrenia who have been incarcerated